<DOC>
	<DOCNO>NCT02052375</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics ( PK ) two dose regimen multiple , subcutaneous ( sc ) injection ASP2408 patient Rheumatoid Arthritis ( RA ) Methotrexate ( MTX ) evaluate pharmacodynamics ( PD ) ASP2408 .</brief_summary>
	<brief_title>A Study To Evaluate Pharmacokinetics , Pharmacodynamics , Safety Tolerability ASP2408 After Multiple Dose Subcutaneous Injections Patients With Rheumatoid Arthritis Methotrexate</brief_title>
	<detailed_description>This ascend dose frequency study . There two cohort active placebo patient . The first cohort dose every 4 week total 3 dos . The second cohort dose every two week total 3 dos .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Subject weigh least 50 kg . Subject body mass index ( BMI ) ≤ 35 kg/m2 . Subject 's 12lead electrocardiogram ( ECG ) result normal Screening Day 1 prior study drug dosing , abnormal , abnormality clinically significant determine Investigator . Subject Rheumatoid Arthritis ( RA ) diagnose accord 1987 revised criterion American College Rheumatology ( ACR ) ≥ 6 month prior Screening . Subject meet ACR 1991 revise criterion Global Functional Status RA , Class I , II III Screening . Subject MUST concomitant methotrexate ( MTX ) : ≥ 3 month prior Day 1 , AND stable dose ( 10 25 mg/week ) ≥ 28 day prior Day 1 throughout study . Subject 's related medication take treatment RA time Screening must meet noted stability requirement remain stable regimen , follow : Nonsteroidal antiinflammatory drug ( NSAIDs ) , selective cyclooxygenase2 ( COX2 ) inhibitor , oral corticosteroid ( ≤ 10 mg prednisone , equivalent , daily ) low dose opioids ( ≤ 30 mg oral morphine , equivalent , daily ) must stable ≥ 28 day prior Screening remain throughout Treatment Observation Period . Hydroxychloroquine ( Plaquenil® ) sulfasalazine must start ≥ 2 month , stable ≥ 28 day , prior Day 1 . Subject ongoing infection infection require intravenous antibiotic within 1 month prior Day 1 . Subject past history serious opportunistic infection . Subject positive Mantoux tuberculin skin QuantiFERONTB Gold test within 90 day , Screening , complete adequate course antimicrobial therapy per CDC guideline . Subject receive live liveattenuated vaccine within 30 day prior Day 1 . Subject receive following : Anakinra ( Kineret® ) , etanercept ( Enbrel® ) , adalimumab ( Humira® ) within 60 day prior Day 1 . Rituximab ( Rituxan® ) antiCD20 antibody within 180 day prior Day 1 . Leflunomide ( Arava® ) within 60 day prior drug dose Day 1 , unless subject undergone cholestyramine washout least 30 day prior Day 1 . Oral injectable gold , azathioprine , penicillamine , cyclosporine , tacrolimus within 30 day prior Day 1 . Cyclophosphamide within 180 day prior Day 1 . Subject receive CTLA4Ig molecule ( include , limited abatacept [ Orencia® ] belatacept [ Nulojix ] ) . Subject participate previous clinical study treatment ASP2408 ASP2409 participate another dose cohort current trial . Subject previously participate interventional clinical study , receive experimental agent within 56 day 5 halflives , whichever longer , prior Day 1 . Subject history prolong QT syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>ASP2408</keyword>
	<keyword>methotrexate</keyword>
</DOC>